The development of immune checkpoint inhibitors, including programmed death-1 and programmed death-ligand 1 (PD-L1) inhibitors, has changed the treatment methods for non—small cell lung cancer (NSCLC). There may be potential interchangeability of the clinical use of certain PD-L1 inhibitors on tumor cell membranes for NSCLC, but not for assessment of PD-L1 expression on immune cells, according to a study.
In a study, published by the Journal of Clinical Oncology, reviewed previously published studies from January 2016 to January 2017 on clinical trial and laboratory-developed PD-L1 immunohistochemistry (IHC) assays (LDAs). The researchers analyzed the effects of diagnostic methods on PD-L1 expression levels in the studies in order to address the practical issues related to tissue samples.
Use of pembrolizumab to treat NSCLC requires PD-L1 IHC testing, but nivolumab and atezolizumab are approved without testing. However, the FDA has approved complimentary PD-L1 tests for both.
“Although PD-L1 IHC testing has value as a biomarker, it has limitations. Research is ongoing to identify novel biomarkers that could be used alone or in combination with PD-L1 expression levels to improve patient selection for immunotherapy,” the researchers concluded.
Following the review, the researchers found that high concordance and interobserver reproducibility were present with the PD-L1 IHC 28-8 pharmDx, PD-L1 IHC 22C3 pharmDx, and Ventana PD-L1 SP263 clinical trial assays for PD-L1 expression on tumor cell membranes. For lower PD-L1 expression was detected with Ventana PD-L1 SP142. Additionally, immune-cell PD-L1 expression was variable and interobserver concordance was poor. Researchers also noted the variable effects on PD-L1 expression for inter- and intraturmoral heterogeneity.
The researchers suggested that the development of LDAs requires standardization before they are used for recommendations in routine clinical use. In addition, the authors noted a need for training or specialized pathologists.
“Interpretation of PD-L1 IHC assays differs from most other IHC assays in the need for appreciation and understanding of the often-heterogeneous morphology of pulmonary tumors,” the authors noted. “Therefore, specialized training is important to maintain consistency and quality of interpretation between pathologists.”
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More